Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Di Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5623-5819; OpenAlex author ID A5100680552. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 2 papers · 2025: 2 papers

Papers 9

  1. Matrix stiffness-sensitive LDHA drives autophagy of pancreatic ductal adenocarcinoma via inducing FOXO3 expression and lactylation. Co-author DOI 10.1016/j.bioadv.2025.214401↗
  2. Acyl-CoA thioesterase 8 induces gemcitabine resistance via regulation of lipid metabolism and antiferroptotic activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41401-025-01477-y↗
  3. Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. Co-author DOI 10.1038/s41416-024-02631-9↗
  4. IL15RA-STAT3-GPX4/ACSL3 signaling leads to ferroptosis resistance in pancreatic cancer. Co-author DOI 10.3724/abbs.2024153↗
  5. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  6. PITX2 in pancreatic stellate cells promotes EMT in pancreatic cancer cells via the Wnt/β-catenin pathway. Co-author DOI 10.3724/abbs.2023118↗
  7. NDUFA4 promotes cell proliferation by enhancing oxidative phosphorylation in pancreatic adenocarcinoma. Co-author DOI 10.1007/s10863-022-09949-0↗
  8. CCL26 is upregulated by nab-paclitaxel in pancreatic cancer-associated fibroblasts and promotes PDAC invasiveness through activation of the PI3K/AKT/mTOR pathw… Co-author DOI 10.1093/abbs/gmab032↗
  9. LncRNA HOTAIR acts a competing endogenous RNA to control the expression of notch3 via sponging miR-613 in pancreatic cancer. Co-author DOI 10.18632/oncotarget.16462↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaowu Xu · 3 shared papers, 2023–2025 · strength 0.59
  2. Yi Qin · 3 shared papers, 2023–2025 · strength 0.59
  3. Xianjun Yu · 3 shared papers, 2023–2024 · strength 0.56
  4. Yue Zhang · 3 shared papers, 2021–2024 · strength 0.51
  5. Jin Xu · 2 shared papers, 2023–2024 · strength 0.36
  6. Si Shi · 2 shared papers, 2023–2024 · strength 0.36
  7. Xuemin Chen · 2 shared papers, 2021–2023 · strength 0.31
  8. Shulong Zhang · 1 shared paper, 2025 · strength 0.25
  9. Tiancheng Gong · 1 shared paper, 2025 · strength 0.25
  10. Xuemin Chen · 2 shared papers, 2017–2022 · strength 0.22
  11. Huihua Cai · 2 shared papers, 2017–2022 · strength 0.22
  12. Xiaoqi Mao · 1 shared paper, 2024 · strength 0.21
  13. Yalan Lei · 1 shared paper, 2024 · strength 0.21
  14. Mingming Xiao · 1 shared paper, 2024 · strength 0.21
  15. Jing Yang · 1 shared paper, 2024 · strength 0.21
  16. Borui Li · 1 shared paper, 2025 · strength 0.21
  17. Zheng Li · 1 shared paper, 2025 · strength 0.21
  18. Qifeng Zhuo · 1 shared paper, 2025 · strength 0.21
  19. Chenjie Zhou · 1 shared paper, 2025 · strength 0.21
  20. Shunrong Ji · 1 shared paper, 2025 · strength 0.21
  21. Xuemin Chen · 1 shared paper, 2024 · strength 0.20
  22. Zhiliang Wang · 1 shared paper, 2024 · strength 0.20
  23. Yang Yang · 1 shared paper, 2023 · strength 0.18
  24. Yue Zhang · 1 shared paper, 2022 · strength 0.16
  25. Xinquan Wu · 1 shared paper, 2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.